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Abstract: Neurocognitive impairment remains an important HIV-associated comorbidity despite
combination antiretroviral therapy (ART). Since the advent of ART, the spectrum of HIV-associated
neurocognitive disorder (HAND) has shifted from the most severe form to milder forms. Independent
replication of HIV in the central nervous system despite ART, so-called cerebrospinal fluid (CSF)
escape is now recognised in the context of individuals with a reconstituted immune system.
This review describes the global prevalence and clinical spectrum of CSF escape, it role in the
pathogenesis of HAND and current advances in the diagnosis and management. It highlights gaps in
knowledge in sub-Saharan Africa where the HIV burden is greatest and discusses the implications
for this region in the context of the global HIV treatment scale up.
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1. Introduction
Globally, 36.7 million people are living with HIV with 21 million of these on antiretroviral
(ART) [1]. Before the advent of ART, HIV-associated central nervous system (CNS) pathology included
opportunistic infections such as cryptococcal meningitis, toxoplasmosis, tuberculosis meningitis and
cytomegalovirus encephalitis, CNS Lymphoma but also HIV encephalitis. Since the rollout of ART,
the incidence of opportunistic infections and primary CNS lymphoma have fallen along with a
reduction in HIV-associated mortality [2]. However, HIV-associated neurocognitive disorder (HAND)
remains an important problem.
A contentious issue is whether independently replicating HIV in the brain parenchyma and
the proxy for this—the presence of HIV virus in the cerebrospinal fluid (CSF), is responsible for
neurocognitive impairment (NCI) in the post-ART era. The terms commonly used are CSF discordance
and CSF escape. The definitions of these terms are based on the quantification of CSF HIV RNA in
paired CSF and plasma specimens (see Table 1). CSF discordance is defined as CSF viral load (VL)
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greater than 0.5 or 1log10 of the plasma VL and CSF escape is defined as any VL in the CSF above the
limit of detection of the assay used (usually 50 copies/mL) when the VL in the plasma is undetectable
by the same assay [3–5]. Although CSF HIV VL does correlate well with brain HIV RNA levels [6],
the causal relationship between CSF escape/discordance and HAND is unclear. This leads to questions
about the utility of CSF HIV RNA as a diagnostic tool for HAND and what level of CSF HIV RNA is
considered to be problematic.
Table 1. Definition of CSF escape and CSF discordance. * Depending on the limit of quantification of
the assay used. Usually 50 copies/mL. VL; Viral Load.
Plasma VL CSF VL
CSF escape Undetectable * Detectable *
CSF discordance Detectable * Greater than 0.5 or 1log10 of the plasma VL
In this review, we describe (1) the prevalence of HAND globally, (2) the clinical spectrum of CSF
escape/discordance (3) the contribution CSF escape/discordance to HIV-associated neurocognitive
disorder (4) critically review the role of CSF HIV RNA and the evolution of HIV drug resistance in the
pathogenesis of CSF escape/discordance, (5) appraise the current state of clinical biomarkers in the
diagnosis of HAND and CSF escape/discordance and (6) review progress with management.
It is worth noting that the majority of research on HAND has been done in Western settings where
Subtype B HIV-1 predominates but little is known about HAND in sub-Saharan Africa (SSA) where
subtypes C, A, D, G and AG predominate. We aim to identify the research gaps globally but highlight
the implications in SSA where the burden of HIV is greatest.
2. Prevalence of HAND in the Post-ART Era
It is clear that since the advent of ART, the prevalence of the most severe form of HAND–HIV
associated dementia (HAD), has markedly reduced [7]. The Multicentre AIDS Cohort Study (MACS),
a USA based study that observed the natural progression of HIV disease, found the incidence of HAD
was 22.3 per 1000 person years in the pre-ART era from 1990 to 1995 [2]. Following the introduction
of ART, the incidence halved to 11.9 per 1000 person years between 1996 and 1998 [2]. However,
the milder forms of HAND; mild neurocognitive disorder (MND) and asymptomatic neurocognitive
impairment (ANI) are increasingly recognised in patients treated with ART [8,9]. The CNS HIV
Antiretroviral Therapy Effects Research (CHARTER) study, another USA based study initiated after
the advent of ART, had 85% of participants on treatment and showed that the spectrum of HAND has
shifted, such that up to 50% of the cohort had HAND but of the least severe type [8]. Similarly, a study
in Switzerland conducted on patients with durable plasma virological suppression, with and without
a cognitive complaints had a prevalence of HAND of 84% and 64% respectively. The proportion of
these with ANI were 24% and 60% respectively [9].
There is evidence to suggest that HIV-1 subtype plays a role in neurocognitive dysfunction.
Neurocognitive impairment has been associated with CRF_02AG when compared with subtype G
in Nigeria [10]. In Uganda, a study found that participants with subtype D virus were at greater risk
of HAD compared to patients with subtype A virus [11]. It is therefore important to know if there
are regional variations in the prevalence of HAND particularly in SSA where the global burden of
HIV-1 is greatest and where sub-type C virus predominates. The diagnosis of HAND is based on the
Frascati Criteria which requires the use of neuropsychological (NP) tests to assess cognitive domains
and determine the extent of decline in performance compared to a normative population together with
an assessment of functional decline (see Table 2) [12]. The prevalence of HAND in sub-Saharan Africa
(SSA) is uncertain because the standard NP tests used to assess cognitive domains require specific
training to deliver and sometimes specialised equipment. In addition, these tests were developed
in resource rich settings and therefore limited by their cultural appropriateness for SSA. The lack of
neurocognitive normative comparison data for this setting is also a limitation [13]. These challenges
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have been partly addressed by various diagnostic accuracy studies and the collection of neurocognitive
normative data [14–18]. In the absence of NP testing, several studies in SSA have attempted to
determine an approximate prevalence of HAND using screening tools. One such screening tool is the
international HIV dementia scale (IHDS), which has fair to moderate sensitivity (45%) and specificity
(79%) in South Africa at a cut off of <11 [14]. In a study in Uganda the sensitivity and specificity
were 80% and 55% respectively [19]. A systematic review of studies using the IHDS to measure
the prevalence of HAND in SSA, amongst patients on ART for at least 6 months, reported a pooled
prevalence of 30.4% (range 4.8% to 80%) [20]. The wide range of prevalence estimates reflect the
heterogeneity of the studies included in the systematic review. Few of the studies excluded patients
with psychiatric presentations, substance abuse, opportunistic infection and none used neuroimaging
to assess for an alternative cause of NCI [20]. This raises questions about diagnostic overestimation.
A prevalence study of HAND in South Africa, using NP testing in treatment naïve persons found a
prevalence of 76% (9% ANI, 42% MND) [21]. Two studies have examined the prevalence of HAND
using NP testing in ART treated persons in South Africa and Malawi and found a prevalence of 66%
(54% MND) [22] and 70% (55% ANI, 12% MND) [17] respectively.
Table 2. Frascati Criteria for diagnosing HIV Associated neurocognitive disorder. ADLs; activities of
daily living. SD; standard deviation.
Asymptomatic Neurocognitive
Impairment (ANI)
Mild Neurocognitive Disorder
(MND)
HIV-Associated Dementia
(HAD)
No interference with ADLs At least mild interferencewith ADLs Marked interference with ADLs
At least 1.0 SD below mean of
normative population in at least
two cognitive domains
At least 1.0 SD below mean of
normative population in at least
two cognitive domains
At least 2.0 SD below mean of
normative population in at least
two cognitive domains
There is controversy around the actual prevalence of HAND because based on these criteria,
the prevalence of HAND is sufficiently high to warrant questions about diagnostic overestimation [23,24].
3. The Spectrum of CSF Escape/Discordance
3.1. Prevalence of CSF Escape/Discordance
In the pre-ART era, HIV encephalitis was common and associated with high CSF viral load [25].
Since the advent of ART, peripheral suppression of HIV-1 has largely been accompanied by suppression
in the CNS. However, this is not the case in every treated individual and the occurrence of CSF
escape/discordance is now recognised [3]. Eden showed in a cross-sectional study of 69 asymptomatic,
virally suppressed patients on ART that the prevalence of CSF escape was 10% [26]. This was followed
up by a retrospective cohort of 75 neurologically asymptomatic patients who had been peripherally
suppressed with an HIV-1 load of <50 copies/mL for a median of 53 months [27]. They found that 36%
of these participants had CSF HIV-1 VL above the lower limit of quantification (20 copies/mL) on at
least one occasion. However repeatedly elevated CSF HIV-1 load was rare (3%) and so the majority
were considered to be CSF blips. The true prevalence of CSF escape in virologically suppressed persons
is uncertain as the prevalence is influenced by the limit of detection of the HIV viral load assay and
the CSF sample volume used. Studies that have used a higher detection limit have reported a lower
prevalence of CSF escape [28,29]. In the Comorbidity in Relation to AIDS (COBRA) cohort study,
where all participants were peripherally suppressed, the prevalence of CSF escape was 1.5% (2/134)
when the limit of detection of CSF HIV-1 was 40 copies/mL [28]. A sub study of participants from the
CHARTER cohort with plasma VL < 50 copies/mL, similarly used a limit of detection of CSF HIV-1 of
40 copies/ml and estimated a prevalence of CSF escape of 1.7% (2/121) [29].
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A retrospective longitudinal study of neurological symptomatic cases from a clinic in Boston
found a prevalence of CSF escape of 6% (12/200) [30]. A retrospective study in the United Kingdom in
HIV positive patients who underwent a clinically indicated lumbar puncture found a prevalence of
CSF discordance and CSF escape of 15% (22/146) and 6% (9/146) respectively [31]. A similar study
from another hospital in the United Kingdom found a prevalence of CSF escape of 11% (16/142) [32].
The PARTITION study prospectively recruited participants with low level viraemia (LLV) and patients
undertaking a clinically indicated lumbar puncture and found the prevalence of CSF discordance of
18% (7/40) and 12% (13/113) respectively [33]. Amongst the National NeuroAids Tissue Consortium
(NNTC) cohort followed up since 1998, 62% of whom had neurological symptoms at the time of lumbar
puncture, the prevalence of CSF escape of 6.8% (26/426) [30]. Mukerji has since described a combined
cohort from CHARTER, NNTC and HIV Neurobehavioural Research Centre (HNRC) with a pooled
prevalence of CSF escape of 7.2% (77/1063) [34]. As of yet, there are no published prevalence studies
of CSF escape/discordance from SSA, so the burden in this region remains unknown.
3.2. The Clinical Presentation
The spectrum of clinical manifestation of CSF escape/discordance in the ART era ranges from
asymptomatic to coma and death. There have been several cases reports and case series describing
patients with chronic HIV on ART with symptomatic CSF escape/discordance [3,4,35–38]. These cases
present with an acute or subacute meningoencephalitis with a broad spectrum of symptoms including
fever, headache, seizure, personality change, psychosis, cortical and subcortical neurological deficits,
coma and death [3,4,35–38].
3.3. Pathogenesis
CSF HIV RNA is thought to be a proxy for independent replication of HIV in the brain
parenchyma as it correlates significantly with brain HIV RNA [6,39]. HIV in the brain is found
in neurones, astrocytes and oligodendrocytes but preferentially infects microglia and perivascular
macrophages [40,41], both of which express the HIV receptor CD4 and co-receptor CCR5 [42]. CSF
escape/discordance is therefore thought to be a reflection of infection of the brain parenchyma. Recent
discovery of a major restriction factor in macrophages, SAMHD1, prompted a rethink as to whether
macrophages could indeed be infected by HIV in the face of this host defence protein, or whether
observed infection was merely the result of engulfment of HIV infected T cells [43]. Subsequent
studies confirmed the ability of SAMHD1 expressing macrophages to sustain HIV infection in CNS
tissue [44,45], most likely explained by the deactivation of SAMHD1 by phosphorylation in sub
populations of macrophages entering early stages of the cell cycle [46]. Drugs such as Etoposide
and Vorinostat have been found to activate SAMDH1, thereby protecting macrophages from HIV-1
infection [47]. These long-lived brain macrophages are key to the establishment of a latent reservoir of
HIV-1 infection in brain and may impact the goals of HIV-1 eradication and functional cure [48].
The pathophysiological process behind asymptomatic and symptomatic CSF escape/discordance
appear to be distinct [49]. In asymptomatic CSF escape, the CSF is acellular and there are no hallmarks
of neuroinflammation; biomarkers for neuronal injury are normal such as neurofilament light chain
protein [26]. The source of HIV RNA is thought to be either through passive trafficking within
infected immune cells from the plasma and subsequent clonal expansion or due to activation of a
latent reservoir from long-lived CNS cells such as macrophages and microglia [40,41]. The presence of
elevated CSF neopterin supports the later [26]. These incidences of CSF escape do not have an impact
on the resistance profile nor appear to be associated with drug CNS penetration effectiveness (CPE)
scores. It is unknown whether these patients go on to develop symptomatic CSF escape.
In symptomatic CSF escape, there is neuroinflammation characteristic of a meningoencephalitis,
with cellular CSF predominated by CD8+ lymphocytes [37,50]. Brain histology supports the presence
of perivascular lymphocytic infiltrates with a CD8+ predominance [4]. This may represent an immune
response to compartmentalised antigen in the CNS and it occurs in the presence of a moderately
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reconstituted immune system, with a respectable CD4 count and so distinct from immune reconstitution
inflammatory syndrome (IRIS) which occurs at low CD4 count [3,4,35–37].
3.4. Risk Factors for CSF Escape/Discordance
There is evidence to suggest that CSF escape/discordance in neurosymptomatic individuals
or participants having a lumbar puncture for clinical reasons is associated with a longer duration
of ART [26,30], low nadir CD4 [26,30,51], ART regimens consisting of a ritonavir-boosted protease
inhibitor (bPI) [34], LLV in plasma [33], history of plasma vial blips [26] low CPE scores [3,4,32] and
frequent drug interruptions [26].
CSF escape has also been described in patients on PI monotherapy [52]. However, in PI
monotherapy drug trials, there have been very few cases reported [53,54]. In the MOST study, 5
of 42 participants on boosted lopinavir developed CSF escape [55]. In the PROTEA sub-study, no
participants out of 71 whom had CSF analyses, developed CSF escape/discordance [56]. Similarly,
in the PIVOT sub-study none of the 11 of 88 participants on PI monotherapy who consented to
have a lumbar puncture had CSF escape [53]. In the MONOI study 2 neurosymptomatic individuals
of the 112 in the PI monotherapy arm were evaluated with CSF analyses and were both found to
have CSF escape [57]. In addition, participants on PI monotherapy have not been found to have
worse performance on NP testing or symptomatic NCI compared to those on triple ART in clinical
trials [54,58]. The interpretation of the association between CSF escape/discordance and bPI is unclear,
as the rationale for bPI monotherapy use in select patients may be a confounder. Patients who are given
bPI monotherapy may be poorly-adherent and bPI is used due to its high barrier to resistance [59] or
may be ill patients and bPI monotherapy is used in order to minimise drug interactions [60] or may
have experienced toxicity from NRTIs and bPI is used as a temporary measure [61]. Boosted PI-based
therapy may represent poor adherence, extensive ART experience and the opportunity for the virus to
have evolved under drug pressure. A combined cohort from CHARTER, NNTC and HNRC found a
3.1-fold increased odds of CSF escape (95% CI 1.9–5.1) on bPI-based triple therapy [34]. Some studies
have not found an association between low CPE scores and CSF escape [26,31,33,62]. This may be
because the value was not adjusted for drug resistance. Peluso found a median CPE score of 6.5 (range,
3–13) but when adjusted for resistance, the median adjusted CPE score was 1 (range, 0–9) [4]. Mukherji
similarly found the median CPE value was 7 (interquartile range [IQR], 7–8), while resistance-adjusted
CPE values were 6 (IQR 4–7) in plasma and 3.5 (IQR 3–4) in CSF [34].
3.5. Genetic Determinants
Independent replication in CSF and blood compartments have been shown [63–66], with greater
genetic diversity of CSF escape viruses compared to plasma viruses according to phylogenetic
analyses of pol/RT [63]. Tong used deep sequencing to explore the range of minority resistance
associated mutations in paired CSF and plasma and discovered mutations in CSF that were not
identified by Sanger sequencing alone [67]. The evolution of resistance mutations is also seen in CSF
viruses [3,30,33,38]. Peluso found CSF viral resistance in patients in whom resistance genotyping was
conducted; 6/7 had NRTI mutations, 5/7 patients had PI mutations and 2/7 patients had NNRTI
mutations [4]. We hypothesise that CSF escape is also associated with peripheral drug resistance.
In Mukherji’s study of the pooled cohort from CHARTER, NNTC and HNRC, the CSF escape cases
were combined with all published CSF cases and showed that M184V/I mutations were detected more
frequently in the CSF and plasma of patients with escape; 61% (34/56) and 30% (16/55) of samples
respectively, compared to participants without escape, where it was only detected in 7% (3/43) of
both CSF and plasma samples [34]. APOBEC3F/G mediated hypermutation has been reported to
be associated with compartmentalisation in CSF compared with peripheral blood mononuclear cells
(PBMCs) and induced drug-resistant mutations in CSF; G73S in protease, M184V and M230I in reverse
transcriptase [68].
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3.6. Neuroimaging
Reported MRI changes in neurosymptomatic CSF escape/discordance are consistent with diffuse
white matter signal abnormality (DWMSA) in the dentate nuclei, brainstem, capsular and subcortical
white matter [4,31,36,69]. A retrospective analysis of HIV-infected adult patients undergoing diagnostic
lumbar puncture at a centre in the United Kingdom found a 10.3 times increased odds of DWMSA
in participants with CSF discordance and a 56.9 times increased odds of DWMSA in participants
with CSF escape [31]. Perivascular enhancement has also been reported [4,69]. The majority of these
demonstrated clinical improvement following ART regimen optimisation. There is little evidence to
guide when to re-image. In a case series of 10 patients, MRI improvements tended to lag behind clinical
improvement by 2 to 12 months. At 60 days, one patient showed resolution of most focal lesions but
the development of a diffuse leukoencephalopathy despite resolution of symptoms. Similarly, another
patient had persistent diffuse white matter hyperintensities on MRI at 111 days, with subsequent
significant decrease in these abnormalities at 346 and 567 days follow-up [4].
3.7. Biomarkers
There are interesting developments in biomarkers of neuropathology and their application to HIV
CNS disease [70]. CSF HIV VL correlates well with brain HIV RNA levels but has not been shown to
correlate with HAND consistently in some studies [6,71,72]. In primary HIV infection (PHI) when HIV
ingresses into the CNS via the blood brain barrier (BBB) or blood CSF barrier (BCSFB), a latent reservoir
is established. There is evidence of neuronal injury at this point with elevated CSF neurofilament light
chain (NFL) protein and also evidence of macrophage activation with elevated CSF neopterin [73].
In PHI where the BBB is known to be leaky, quotient Albumin (QALB) (CSF/plasma albumin ratio), a
marker of endothelial tight joint permeability is elevated and directly correlates with NFL [73].
Amongst ART treated, neurocognitively unimpaired persons, for most part, CSF neopterin
usually decreases to normal levels [73–75]. Neopterin remains mostly elevated in those with HAND
despite achieving peripheral virological suppression [51,74]. This potentially makes it a useful
indicator of HAND, although diagnostic accuracy studies need to be done. NFL may be a useful
biomarker for severe NCI. Although it is not disease-specific, it has been found to be mostly normal
in those with Alzheimer’s Disease [76] but is largely elevated in those with HAD and untreated
neuroasymptomatics with low CD4 counts [77,78]. Although inconclusive due to insufficient power,
another study investigating if ANI or MND was associated with neuronal damage found that CSF
NFL was higher in individuals with NCI compared with neurocognitively normal individuals but did
not predict progressive neurocognitive decline [51]. In patients with HAD, there is also evidence of
injury to unmyelinated cortical axons evidenced by elevated total-tau. [79].
The published data on biomarkers in CSF escape/discordance are limited. However, case series
have reported evidence of immune activation with elevated neopterin in CSF but not plasma in
both symptomatic [4] and asymptomatic cases [26,62] of CSF escape. Markers of BBB dysfunction
are evident with elevation of the matrix metalloproteinases MMP-2, 3 and 9 and subsequent
elevation of their inhibitors TIMP-1 and 2 [80]. Other inflammatory mediators are elevated such
a sCD14—a marker of macrophage activation [80]; chemokines—CCL3, CCL4, CCL5 and CXCL10;
cytokines—IL-1α/β, IL-1RA, IL-8, IL-10; TNF related proteins—TNFα, TNFR1, TNFR2 and TRAIL;
adhesion molecules; VCAM and ICAM [5,80]. The presence of these inflammatory mediators show that
CSF escape/discordance is associated with neuroinflammation, which is occurring in the context of a
reconstituted immune system, which may be responsible for both the inflammation and viral replication
by attracting HIV infected immune cells or activating latent reservoirs [81]. These inflammatory
mediators are significantly higher in the CSF compared to plasma and suggests intrathecal production
and that the CNS cellular immune response to viral antigen is compartmentalised [62,80]. NFL has
been shown to be elevated in symptomatic CSF escape but slowly normalises as CNS viral suppression
is achieved [80]. NFL lends itself to being used as a non-invasive clinical test as plasma NFL, although
50-fold lower, correlates strongly with CSF NFL (r = 0.89, p < 0.0001) [77].
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3.8. Treatment Options
ART as well as being neuroprotective [82], improves neuropsychological functioning and reduces
neurological abnormality [83]. There are no evidence-based interventions to guide the best treatment
strategies in neurosymptomatic patients with CSF escape/discordance and recommendations are
based on expert opinion. In case reports and case series, optimising ART to improve brain penetration
has been found to improve symptoms and reduce CSF VL in symptomatic individuals [3,4,35,69,84].
The British HIV Association and European Aids Clinical Society guidelines suggest that in those with
a detectable viral load in the CSF, an assessment for CSF HIV resistance should be undertaken and
ART optimised to the resistance profile [61]. The MIND exchange program similarly recommends
modifying the ART regimen to improve the CPE score and target the CSF viral resistance profile [85].
One published study used 1 g of intravenous methylprednisolone for 5 days followed by a tapering
dose of oral prednisolone to treat neurosymptomatic CSF escape/discordance with mixed results [37].
Although neurosymptomatic CSF escape/discordance is accompanied by a degree of compartmentalised
neuroinflammation, there are insufficient data to recommend the use of corticosteroids in this context.
4. Association between CSF Escape/Discordance and HAND
In the era of ART, the neuropathogenesis of HAND is not simply due to viral replication
and neuroinflammation but with multifactorial contribution including the legacy of neuronal
injury, HIV-induced metabolic changes, neurotoxicity of ARTs and poor drug penetration [81,86].
Other recognised associations with HAND include comorbid factors such as, drugs and alcohol, liver
disease and illiteracy [8]. In ART naïve patients in South Africa, older age and fewer years of education
were associated with HAND [21].
A cross-sectional study of the NNTC cohort of post-mortem brain tissue showed that the presence
of brain HIV RNA did not correlate well with HAND diagnosed in the absence of features associated
with HIV-replication, that is, HIV encephalitis or microglial nodule encephalitis. However, a higher
brain HIV RNA level correlated with worse performance on NP tests [6]. This suggests that the
mere presence of HIV in the brain is not sufficient to cause neurocognitive dysfunction and that
replication with the attendant neuroinflammation may be necessary. It is further support that CSF
escape/discordance as a reflection of brain parenchymal HIV replication [6,39], is important in the
pathogenesis of HAND.
CSF escape/discordance is reported in patients with HAND. The detection of HIV-1 in CSF even
at low-level (<50 copies/mL) using single copy assay was 12.7% in a CHARTER subgroup study [87].
In this cohort, low-level CSF viraemia at any level was correlated with worse neurocognitive performance
(r = −0.20, p = 0.002) and the presence of CSF escape at first or second visit was associated with a decline
in neurocognitive performance compare to those without CSF escape (p = 0.02) [87]. In Mukherji’s pooled
cohort, symptomatic neurocognitive impairment was more frequent in participants with CSF escape
compared to participants without CSF escape (35% vs. 20%) [34].
Although the precise contribution of CSF escape/discordance to HAND is unclear, independent
replication of HIV-1 in the brain likely contributes to neurocognitive decline particularly in the
context of drug resistance. As CSF escape/discordance is a potentially modifiable risk factor for
neurocognitive decline, there does appear to be a role for detecting, quantifying and sequencing CSF
HIV RNA in HAND diagnosis and management [61,85,88]. There are no published studies examining
the association between CSF escape/discordance and HAND in SSA.
5. Research Gaps in Sub-Saharan Africa and Proposed Future Research
5.1. Determining the Prevalence of HAND
Diagnosing HAND has challenges in this setting. It requires a battery of NP tests, that require
a specific skill set to deliver and sometimes specialised equipment. These tests were developed
in resource-rich settings [13] and until recently normative scores did not exist for resource-limited
Brain Sci. 2018, 8, 190 8 of 14
settings (RLS) [15,18]. Studies compiling normative comparative data in RLS have largely used small
convenience samples [14,17,18,22,89]. Two studies have collected large-scale, comprehensive normative
neurocognitive data in RLS, using broadly representative participants of the local HIV-negative
population and found country specific differences in NP performance [15,90]. This highlights the
need for further research to firstly evaluate NP tests in SSA to limit cultural bias and inform on the
appropriate NP tests to use for each setting. Secondly, there is a need for comprehensive collection of
neurocognitive normative comparison data from HIV-negative controls in SSA.
5.2. Pathogenesis of HAND
The biological causes of HAND in ART treated patients in SSA are not well understood however
there is evidence to suggest that HIV-1 subtype may play a role [10,11]. Most of the published studies
on the pathogenesis of HAND comes from Europe and USA where subtype B HIV-1 predominates.
It is therefore important to study the mechanisms driving HAND and CSF escape/discordance in SSA,
where the global burden of HIV is greatest and where subtypes C, A, D, G and AG HIV-1 predominate.
5.3. CSF Escape/Discordance
There are currently no published data on CSF escape/discordance from SSA. Based on the current
knowledge of risk factors for CSF escape/discordance, which include long duration on ART, low nadir
CD4 count, LLV, history of plasma viral blips and frequent drug interruptions, together with the rise in
the prevalence of pretreatment drug resistance in RLS [91], it is hypothesised that the prevalence of CSF
escape/discordance will be higher in SSA compared to data published from resource rich settings. Due
to the high prevalence of pretreatment drug resistance in RLS there are imminent plans to change the
standard first line ART regimen in SSA from NNRTI-based to dolutegravir-based triple therapy [92],
it is important to determine the prevalence of CSF escape/discordance on this new regimen. Going
forward, dual therapy may have a role in treatment simplification in virologically suppressed patients
in SSA and it would similarly be important to determine the prevalence of CSF escape/discordance on
these regimens.
Further research should aim to determine the prevalence, the clinical spectrum and pathophysiology
in symptomatic and asymptomatic patients, the genetic variability of compartmentalised viruses,
the evolution of drug resistance in this setting, as well as the role of HIV-1 subtypes in the pathogenesis
of CSF escape/discordance. Prospective follow up studies are required to determine if asymptomatic
persons with CSF escape will progress to symptomatic CSF escape.
5.4. Clinical Biomarkers
No studies in SSA have systematically evaluated plasma or CSF biomarkers in ART treated person
with CSF escape/discordance. Investigating biomarkers may pave the way to developing useful,
non-invasive diagnostic tests for assessing and managing patients with neurological involvement
of HIV-1.
6. Conclusions
The overwhelming view is that in the era of cART, the neuropathogenesis of HAND is not simply
due to viral replication and consequent neuroinflammation but a multifactorial aetiology including
the legacy of neuronal injury, HIV-induced metabolic changes, neurotoxicity of ARTs, poor drug
penetration, drugs and alcohol and liver disease. CSF escape/discordance does however appear to
have an independent role in NCI. Furthermore, the presence of ongoing replication in the CNS may be
a barrier to HIV-1 eradication and the goal of achieving a cure.
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